FR108F - - Google Patents

Info

Publication number
FR108F
FR108F FR108DF FR108F FR 108 F FR108 F FR 108F FR 108D F FR108D F FR 108DF FR 108 F FR108 F FR 108F
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DET20558A external-priority patent/DE1173904B/de
Application filed filed Critical
Application granted granted Critical
Publication of FR108F publication Critical patent/FR108F/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR108D 1961-08-04 1964-06-22 Expired FR108F (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DET20558A DE1173904B (de) 1961-08-04 1961-08-04 Verfahren zur Herstellung von 2-[5', 6', 7', 8'-Tetrahydronaphthyl-(1')-aminol]-imidazolin und seinen Salzen
DET24192A DE1191381B (de) 1961-08-04 1963-06-24 Verfahren zur Herstellung von 2-[5', 6', 7', 8'-Tetrahydronaphthyl-(1')-amino]-imidazolin und seinen Salzen

Publications (1)

Publication Number Publication Date
FR108F true FR108F (fr) 1966-03-14

Family

ID=39182378

Family Applications (2)

Application Number Title Priority Date Filing Date
FR979160A Expired FR93451E (fr) 1961-08-04 1964-06-22 Procédé de fabrication d'une 2-(tétrahydronaphtyl-1')-amino-imidazoline.
FR108D Expired FR108F (fr) 1961-08-04 1964-06-22

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR979160A Expired FR93451E (fr) 1961-08-04 1964-06-22 Procédé de fabrication d'une 2-(tétrahydronaphtyl-1')-amino-imidazoline.

Country Status (5)

Country Link
BE (1) BE649602A (fr)
BR (1) BR6460180D0 (fr)
DE (1) DE1191381B (fr)
FR (2) FR93451E (fr)
SE (1) SE325895B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180721A (en) * 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5281591A (en) * 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5252595A (en) * 1990-02-28 1993-10-12 Allergan, Inc. Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
US5151440A (en) * 1990-02-28 1992-09-29 Allergan, Inc. Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenyl-amino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
US5066664A (en) * 1990-02-28 1991-11-19 Allergan, Inc. 2-(hydroxy-2-alkylphenylamino)-oxazolines and thiazolines as anti-glaucoma and vasoconstrictive agents
US5580892A (en) * 1993-10-22 1996-12-03 Allergan Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2899426A (en) * 1959-08-11 Synthesis of l
CH338464A (de) * 1955-12-19 1959-05-31 Wander Ag Dr A Verfahren zur Herstellung eines 2-Amino-imidazolins

Also Published As

Publication number Publication date
BE649602A (fr) 1964-12-22
FR93451E (fr) 1969-04-04
DE1191381B (de) 1965-04-22
SE325895B (fr) 1970-07-13
BR6460180D0 (pt) 1973-07-26

Similar Documents

Publication Publication Date Title
AT224007B (fr)
BE600261A (fr)
BE567723A (fr)
BE600667A (fr)
BE458606A (fr)
BE475425A (fr)
BE472265A (fr)
BE617033A (fr)
BE602045A (fr)
BE469342A (fr)
BE601393A (fr)
BE164003A (fr)
BE601844A (fr)
BE602469A (fr)
BE601679A (fr)
BE601847A (fr)
BE601041A (fr)
BE598861A (fr)
BE600768A (fr)
BE621065A (fr)
BE599016A (fr)
BE597570A (fr)
SE325895B (fr)
BE601846A (fr)
BE475477A (fr)